Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E26.92 EPS (ttm)1.19 Insider Own0.04% Shs Outstand6.01B Perf Week-3.02%
Market Cap192.91B Forward P/E11.69 EPS next Y2.75 Insider Trans-6.67% Shs Float5.94B Perf Month-4.52%
Income7.30B PEG4.77 EPS next Q0.66 Inst Own72.50% Short Float0.80% Perf Quarter-4.46%
Sales52.60B P/S3.67 EPS this Y5.20% Inst Trans-1.37% Short Ratio2.11 Perf Half Y1.23%
Book/sh9.73 P/B3.30 EPS next Y7.64% ROA4.20% Target Price37.53 Perf Year-4.80%
Cash/sh2.42 P/C13.25 EPS next 5Y5.64% ROE12.00% 52W Range29.83 - 37.39 Perf YTD-1.11%
Dividend1.28 P/FCF28.71 EPS past 5Y3.30% ROI7.80% 52W High-14.09% Beta1.02
Dividend %3.99% Quick Ratio1.10 Sales past 5Y-2.80% Gross Margin77.30% 52W Low7.68% ATR0.34
Employees96500 Current Ratio1.40 Sales Q/Q-1.70% Oper. Margin18.00% RSI (14)23.07 Volatility1.10% 0.93%
OptionableYes Debt/Eq0.75 EPS Q/Q5.00% Profit Margin13.90% Rel Volume1.13 Prev Close32.46
ShortableYes LT Debt/Eq0.62 EarningsMay 02 BMO Payout100.70% Avg Volume22.43M Price32.12
Recom2.50 SMA20-3.47% SMA50-4.94% SMA200-3.34% Volume25,356,700 Change-1.05%
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
May-22-17 08:42AM  The 3 Best Dividend Stocks in Arthritis Medication Motley Fool
May-21-17 07:41AM  3 Ways Johnson & Johnson's Pharmaceutical Business Plans to Beat the Market Motley Fool
May-20-17 07:22AM  3 Stocks to Supplement Your Social Security Income Motley Fool
May-19-17 05:47PM  [$$] Iterum Therapeutics Lines Up Funding Ahead of Trials The Wall Street Journal
02:05PM  ETFs with exposure to Pfizer Inc. : May 19, 2017 Capital Cube
12:12PM  Billionaire George Soros Is Warming Up to This Big Pharma Stock. Should You? Motley Fool
08:38AM  CHMP backs Novartis's Zykadia for first-line use in lung cancer Reuters
May-18-17 03:44PM  Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments Investor's Business Daily
09:36AM  Pfizer Inc. :PFE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017 Capital Cube
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific Zacks
09:00AM  The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis PR Newswire
07:37AM  A Doomed Trump Presidency Would Be a Terrifying Development for Pharmaceutical Stocks Motley Fool
07:30AM  [$$] Some Biotech Companies Making the Cut in Narrower IPO Market The Wall Street Journal
May-17-17 08:00PM  Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting Business Wire
08:00PM  Astellas Announces Oncology Portfolio Updates PR Newswire
05:00PM  Pfizer drug from Medivation deal shows promise in breast cancer -study Reuters
01:25PM  Stock Market Today & Home Depot, Pfizer and ConocoPhillips Research Reports Zacks
12:39PM  Eli Lilly: Worries Ahead In Patent Fight Barrons.com
11:00AM  Pfizer Invites Public to View and Listen to Webcast of June 9 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations Business Wire
09:42AM  3 Dividend Stocks Perfect for Senior Citizens Motley Fool
08:00AM  Today's Research Reports on Stocks to Watch: BlackBerry and Pfizer Accesswire
07:53AM  Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal Zacks
May-16-17 04:37PM  [$$] US retail real estate extends its bruising slide Financial Times
04:35PM  US STOCKS-S&P 500, Dow end session flat, tech boosts Nasdaq Reuters
04:13PM  Dow's Pfizer, Eli Lilly Topple To 3-Month Lows On Downgrades Investor's Business Daily
04:04PM  Yum Brands, Intuitive Surgical Called Buys; Pfizer Cut To Sell Investor's Business Daily
03:05PM  US STOCKS-S&P 500 falls on mixed data, Nasdaq helped by tech stocks Reuters
01:20PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
01:15PM  US STOCKS-Wall St flat after S&P, Nasdaq hit record highs Reuters
01:07PM  Pfizer: Is It Time To Sell? Barrons.com
12:34PM  Jim Cramer Talks Home Depot, TJX Companies, Ford, Apple, Pfizer, Nike, Target and Alibaba TheStreet.com
12:17PM  Eli Lilly: Has This Bloom Begun To Wilt? Barrons.com
11:39AM  US STOCKS-Wall St retreats after S&P, Nasdaq hit record highs Reuters
11:15AM  Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns Benzinga
10:47AM  Jim Cramer -- Citi's Downgrade of Pfizer Not Totally Reasonable TheStreet.com
09:48AM  US STOCKS-S&P, Nasdaq hit record highs on gains in tech, consumer staples Reuters
08:13AM  Early movers: HD, PFE, BABA, DKS, YHOO, F, VOD, FB, JNJ & more CNBC
07:30AM  Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy PR Newswire
May-14-17 11:01AM  Here's Why the Best Is Yet to Come for Pfizer Inc. Motley Fool
May-12-17 06:01PM  What happens to corporate crime cases with the FBI in flux? Associated Press
05:19PM  Tepper's Appaloosa Trims Bets on Pharmaceuticals The Wall Street Journal
04:20PM  Why Sangamo Therapeutics Inc. Jumped Higher Today Motley Fool
01:43PM  These guys put the 'activist' in activist investing CNBC
08:49AM  Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study Zacks
May-11-17 10:30AM  Why Sangamo Therapeutics Is Surging 24/7 Wall St.
May-10-17 07:43PM  Why Roche's Cancer Failure Might Tank Bristol, Pfizer But Not Merck Investor's Business Daily
05:18PM  Sangamo shares jump on Pfizer collaboration, quarterly results MarketWatch
04:01PM  Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy PR Newswire
03:28PM  Allergan Starts 'Pivotal' 2017 With a Beat, Plus Jim Cramer's Take TheStreet.com
01:01PM  Pfizer Inc. : PFE-US: Dividend Analysis : May 12th, 2017 (record date) : By the numbers : May 10, 2017 Capital Cube
09:30AM  [$$] Going public benefits workers and investors Financial Times
04:56AM  Roche's star cancer drug stumbles in study, raising doubts about future Reuters
May-09-17 09:31PM  Edited Transcript of PFE earnings conference call or presentation 2-May-17 2:00pm GMT Thomson Reuters StreetEvents
05:12PM  Pfizer immuno-oncology drug wins U.S. approval for bladder cancer Reuters
05:03PM  FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer PR Newswire
03:53PM  FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer PR Newswire
01:00PM  Buy 'repatriation stocks' because that is sure to make the cut in the final tax bill, UBS says CNBC
12:47PM  Pfizer immuno-oncology drug wins U.S. approval for bladder cancer Reuters
09:06AM  Comparing Pfizers Valuation to Peers after 1Q17 Earnings Market Realist
07:35AM  Pfizers Corporate and Pipeline Developments in 1Q17 Market Realist
May-08-17 04:00PM  M&A Talks May Take Center Stage in Allergan's 1Q Earnings Call TheStreet.com
03:21PM  Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales TheStreet.com
10:36AM  Pfizers Key Product Developments in 1Q17 Market Realist
10:00AM  Collaboration Helps Broaden Access to Pfizers Contraceptive, Sayana® Press (medroxyprogesterone acetate), for Women in Some of the Worlds Poorest Countries Business Wire
09:34AM  J&J: What's In Store At Next Week's Analyst Meeting Barrons.com
09:06AM  Pfizer: Why Revenues Fell in 1Q17 for Some Products Market Realist
08:46AM  Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit Zacks
07:37AM  Pfizer: Understanding Growth Drivers in 1Q17 Market Realist
May-05-17 05:36PM  Pfizers Geographical Performance in 1Q17 Market Realist
05:04PM  Dow 30 Stock Roundup: Apple, Merck Beat; Pfizer Misses on Revenues Zacks
04:37PM  Merck vs. Pfizer: Which Stock Looks Better Post-Earnings? Zacks
04:05PM  Pfizers 1Q17 Earnings: A Look at Revenues by Segment Market Realist
03:56PM  Deals of the Week: Waiting for Clarity TheStreet.com
03:34PM  U.S. chief justice taps New York judge to handle Puerto Rico bankruptcy Reuters
02:17PM  Analyzing Pfizers 1Q17 Earnings Market Realist
May-03-17 05:25PM  Phase 3 OCTAVE Studies of Oral Tofacitinib in Ulcerative Colitis Results Published in The New England Journal of Medicine Business Wire
04:31PM  Bristol-Myers 'Too Risky' To Acquire As Merck, Roche Pile On Pressure Investor's Business Daily
02:02PM  Pfizer Must Learn to Live With Uncertainty Bloomberg
10:33AM  Bristol-Myers: Going Stag to the Ball? Barrons.com
10:32AM  Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat Zacks
09:00AM  Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis Business Wire
08:58AM  Dow Jones Industrial Average And Dow Stocks: News And Analysis Investor's Business Daily
07:30AM  Investors Rest Easy After Pfizer and Merck Release Solid Q1 Earnings Reports Accesswire
03:07AM  Asian stocks lower ahead of US Federal Reserve meeting Associated Press
May-02-17 04:27PM  Dow's Pfizer Tops Earnings Views, But Sales Come Up Short Investor's Business Daily
01:27PM  Trump's 'tax holiday' could be a windfall for these stocks CNBC
01:06PM  Pfizer beats 1Q profit forecasts, but sales slip Associated Press
12:58PM  Prescription for growth at Pfizer? Analysts say deals Reuters
12:37PM  Four CNBC IQ 100 components are down big today CNBC Videos
12:00PM  Patent Losses, Prevnar Weakness Weigh on Pfizer Growth Morningstar
11:59AM  Pfizer: We Could Be Here a While Barrons.com
11:58AM  Dow Higher On Intel Gain; Apple Q2 Earnings After The Close Investor's Business Daily
11:37AM  [$$] Pfizer Revenue Falls as Drugs Lose Exclusivity The Wall Street Journal
11:17AM  Pfizer and Apple In Focus Zacks
10:48AM  Pfizer Sill Desperately Seeking Revenue Growth Investopedia
10:20AM  On Pfizer and Apple: 2 Titanic Stocks Reporting Earnings Today Zacks
10:03AM  US STOCKS-Wall St flat as Fed meet kicks off; Nasdaq hits record Reuters
09:41AM  Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact Zacks
09:30AM  Zacks Investment Ideas feature highlights: Tesla, Pfizer, Apple and Facebook Zacks
09:18AM  Stocks to Watch: Aetna, Pfizer, Apple The Wall Street Journal
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; and collaborative agreements with Eli Lilly & Company and Merck KGaA. It also has a research collaboration and license agreement with HitGen Ltd. to build and screen DNA-encoded libraries in order to discover small molecule leads to be used in drug development; and an agreement with InSphero AG to develop a predictive toxicology assay using InSphero 3D InSight human liver microtissues for predicting drug induced liver injury. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSON RADY AExecutive Vice PresidentMar 10Sale34.194,500153,85554,963Mar 13 05:36 PM
HILL CHARLES HExecutive Vice PresidentMar 09Sale34.0736,0001,226,52057,329Mar 10 03:59 PM
Dolsten MikaelPresident R&DMar 02Sale34.5515,401532,10549,318Mar 03 04:06 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 02Sale34.6620,000693,20083,793Mar 03 04:06 PM
Dolsten MikaelPresident R&DMar 01Sale34.4815,569536,81964,719Mar 03 04:06 PM
Dolsten MikaelPresident R&DFeb 27Sale34.2658,8462,016,24480,288Mar 01 05:10 PM
JOHNSON RADY AExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63572,172Feb 27 06:30 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 23Option Exercise21.03103,1552,169,350295,356Feb 27 06:30 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 23Option Exercise21.0351,5781,084,685138,758Feb 27 06:30 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63533,848Feb 27 06:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 23Option Exercise21.03218,4474,593,940592,765Feb 27 06:21 PM
BOURLA ALBERTGroup PresidentFeb 23Option Exercise21.0342,476893,270165,474Feb 27 06:21 PM
Dolsten MikaelPresident R&DFeb 23Option Exercise21.03218,4474,593,940299,915Feb 27 06:21 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 23Option Exercise21.0336,408765,660102,611Feb 27 06:10 PM
READ IAN CChairman & CEOFeb 23Option Exercise21.03788,83516,589,2001,124,093Feb 27 06:55 PM
SUSMAN SALLYExecutive Vice PresidentFeb 23Option Exercise21.03115,2912,424,570247,765Feb 27 06:55 PM
YOUNG JOHN DGroup PresidentFeb 23Option Exercise21.0351,5781,084,685172,542Feb 27 06:56 PM
OLSON LAURIE JExecutive Vice PresidentFeb 23Option Exercise21.0327,306574,24599,224Feb 27 06:47 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 07Option Exercise25.8730,000776,100167,687Dec 08 09:48 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 09Sale33.0010,000330,000112,087Nov 10 07:44 PM
BOURLA ALBERTGroup PresidentNov 04Option Exercise24.9920,000499,800149,199Nov 07 05:58 PM
BOURLA ALBERTGroup PresidentNov 04Sale30.0518,390552,530130,809Nov 07 05:58 PM
HILL CHARLES HExecutive Vice PresidentNov 03Option Exercise21.0353,9181,133,896115,033Nov 07 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 02Option Exercise21.0332,545684,421122,087Nov 04 04:36 PM
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM